#USA #Los Angeles #Schall Law Firm #Securities Fraud #Mereo BioPharma

Legal Opportunity for Investors in Mereo BioPharma

Mereo BioPharma Group plc, a firm listed on NASDAQ as MREO, is currently facing a class action lawsuit initiated by the Schall Law Firm, a prominent national shareholder rights litigation firm. Investors who acquired Mereo’s securities between June 5, 2023, and December 26, 2025, may have incurred losses due to alleged securities fraud. This development presents an opportunity for shareholders to seek justice and support amidst the ongoing litigation.

Background on Mereo BioPharma

Mereo BioPharma focuses on the discovery and development of innovative medicines for patients with rare diseases and significant unmet medical needs. However, the company has come under scrutiny due to purported violations of the Securities Exchange Act of 1934, specifically concerning misinformation related to its clinical trials. The lawsuit alleges that Mereo made misleading statements regarding the effectiveness of its Phase 3 clinical trials known as ORBIT and COSMIC.

Class Action Details

The legal action against Mereo is based on accusations that the company failed to disclose critical information about its clinical trial outcomes. Reports indicate that both ORBIT and COSMIC did not achieve their primary endpoints, a disclosure that could have influenced investor decision-making. The Schall Law Firm is urging affected investors to connect with their office before the April 6, 2026, deadline to explore their rights and consider joining the lawsuit.

How Investors Can Participate

Shareholders who believe they have been negatively impacted are encouraged to reach out to the Schall Law Firm for guidance. Interested parties can contact Brian Schall directly at 310-301-3335, or they can submit inquiries through the firm’s website, where further information regarding participation is available. Engaging in this action may provide an avenue for recovering financial losses incurred during the class period.

Importance of Legal Representation

As of now, the class has yet to be certified, implying that investors may not yet have formal legal representation. Those who opt not to participate in the lawsuit will remain as absent class members, potentially missing out on recovery opportunities. Therefore, securing knowledgeable legal counsel during this time is crucial.